Journal
BRITISH JOURNAL OF CANCER
Volume 95, Issue 8, Pages 955-960Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603353
Keywords
rapamycin; kinase inhibitors; mammalian target of rapamycin (mTOR); resistance mechanisms; cap-dependent translation; clinical resistance
Categories
Funding
- NCI NIH HHS [CA21675, CA23099, CA96696, R01 CA096696, CA77776, R01 CA077776, P01 CA023099] Funding Source: Medline
Ask authors/readers for more resources
The serine/threonine kinase, mTOR ( mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available